Review of health-related quality of life data in multiple myeloma patients treated with novel agents

Leukemia

Volumn 27, Issue 10, 2013, Pages 1959-1969

  Sonneveld, P ^a   Verelst, S G ^a   Lewis, P ^b   Gray Schopfer, V ^c   Hutchings, A ^d   Nixon, A ^e   Petrucci, M T ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Celgene GmbH   (Germany)

^c OmniScience SA   (Switzerland)

^d Global Market Access Solutions   (United Kingdom)

^e ICON PLC   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

bortezomib; lenalidomide; multiple myeloma; quality of life; thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

CANCER GROWTH; CANCER SURVIVAL; COCHRANE LIBRARY; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; EMBASE; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; QUALITY OF LIFE;

EID: 84885583274     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.185     Document Type: Review

References (100)

1. Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 2009; 83: 139-148.
2. Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 1980; 302: 310-315.
3. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010; 24: 1043-1049.
4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
5. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27: 423-429.
6. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579.
7. Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 2012; 26: 2424-2428.
8. Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improving survival in multiple myeloma: impact of novel therapies. Proceedings of the 49th Annual Meeting of the American Society of Hematology (ASH), Atlanta, GA; USA. Blood 2007; 110: Abstract 3954.
9. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL,MunshiNC, Ghobrial IMet al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222-2232.
10. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
11. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993-1999.
12. Verelst SGR, Blommestein HM, Karim-Kos HE, Huijgens PC, Sonneveld P. Trends in incidence and survival of multiple myeloma in the Netherlands in the last wo decades. Results from a national population based study. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 5071.
13. Verelst S, Karim-Kos H, Blommestein H, Sonneveld P. Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands. Proceedings of the 17th Congress of the European Hematology Association (EHA), Amsterdam, The Netherlands. Haematologica 2012; 97: 242.
14. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
15. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
16. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final timeto-event results of the APEX trial. Blood 2007; 110: 3557-3560.
17. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
18. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
19. Larocca A, Palumbo A. Evolving paradigms in the treatment of newly diagnosed multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1186-1196.
20. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011; 17: 1253-1263.
21. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
22. Sonneveld P, Schmidt-Wolf I, van der Holt B, el Jarari L, Bertsch U, Salwender H et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Proceedings of the 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA. Blood 2010; 116: Abstract 40.
23. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456.
24. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
25. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
26. Hahn-Ast C, von Lilienfeld-Toal M, van Heteren P, Mü ckter S, Brossart P, Glasmacher A. Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analyis of five randomized trials. Proceedings of the 16th Congress of the European Hematology Association (EHA), London, United Kingdom. Haematologica 2011; 96: 367 Abstract 0884.
27. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 2010; 24: 1406-1411.
28. Bang SM, Kyle RA, Rajkumar SV, Kumar S. Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia 2013; 27: 971-974.
29. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
30. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
31. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011; 25: 689-696.
32. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-2266.
33. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
34. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
35. Palumbo A, Adam Z, Kropff M, Foa R, Catalano J, Gisslinger H et al. A phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts)X65 years (yrs) with newly diagnosed multiple myeloma (NDMM): updated results for pts aged 65-75 yrs enrolled in MM-015. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 475.
36. Palumbo A, Mateos MV, Bringhen S, San Miguel JF. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 2011; 25: 181-191.
37. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26: 595-608.
38. Jordan K, Ishak JK, Lewis P, Proskorovsky I, Payne KA, Lordan N et al. Determinants of global QOL and physical and social functionality in multiple myeloma. Proceedings of the 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA. Blood 2010; 116: Abstract 934.
39. Schumacher A, Kessler T, Buchner T, Wewers D, van de Loo J. Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy-A longitudinal study. Leukemia 1998; 12: 586-592.
40. Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013; 27: 1511-1519.
41. Alibhai SM, Leach M, Kowgier ME, Tomlinson GA, Brandwein JM, Minden MD. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia 2007; 21: 845-848.
42. Koenigsmann M, Koehler M, Franke A, Frommer J. Acute leukaemia in adults: researching the patient's perspective. Leukemia 2006; 20: 206-207.
43. European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products:EMEA/CHMP/EWP/139391/2004 2004.
44. US Department of Health and Human Services Food and Drug Administration Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009.
45. Bottomley A, Efficace F, Fayers PM. Standards are needed for quality of life clinical trials. BMJ 2002; 324: 1156.
46. Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 2000; 53: 451-458.
47. Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S et al. Effect of thalidomide with melphalan and prednisone on healthrelated quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 2011; 90: 1427-1439.
48. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116: 1405-1412.
49. Gulbrandsen N, Waage A, Gimsing P, Turesson I, Juliusson G, Abildgaard N et al. A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Proceedings of the 13th Congress of the European Hematology Association (EHA), Copenhagen, Denmark. Haematologica 2008; 93: 84 (Abstract 0209).
50. Hjorth M, Hjertner O, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT et al. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 2012; 88: 485-496.
51. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 2010; 28: 3160-3166.
52. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M et al. Thalidomide for previously untreated elderly patients with multiple myeloma: metaanalysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118: 1239-1247.
53. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
54. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107-3114.
55. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95: 311-319.
56. Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 2010; 84: 345-353.
57. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
58. Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 2006; 24: 976-982.
59. Viala M, Bhakar AL, de la Loge C, van de Velde H, Esseltine D, Chang M et al. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol 2007; 60: 670-679.
60. Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008; 143: 511-519.
61. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
62. Delforge M, Dhawan R, Robinson Jr. D, Meunier J, Regnault A, Esseltine DL et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial. Eur J Haematol 2012; 89: 16-27.
63. Dubois D, Ravinder D, van de Velde HA, Esseltine D, Gupta S, Viala M et al. Use of patient-reported outcomes (PROs) to assess prognosis, toxicity, and response: The bortezomib experience in relapsed and refractory multiple myeloma (MM). Proceedings of the 46th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2004; 104: Abstract 3468.
64. Lee S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Jagannath S et al. For the SUMMIT Investigators. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. 2003 ASCO Annual Meeting Proceedings. J Clin Oncol 2003; 22: Abstract 2339.
65. Lee SJ, Richardson PG, Sonneveld P, Schuster M, Irwin D, Massaro J et al. Healthrelated quality of life (HRQL) associated with bortezomib compared with highdose dexamethasone in relapsed multiple myeloma (MM): results from APEX study. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23: Abstract 6535.
66. Dhawan R, Meunier J, Regnault A, Rosa K, Robinson D, Cakana A et al. Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial. XII International Myeloma Workshop (IMW), Washington DC; USA. Clin Lymphoma Myeloma 2009; 9: S58 (Abstract 352).
67. Dhawan R, Robinson D, Meunier J, Regnault A, Rosa K, Cakana AZ et al. Sustained health-related quality of life (HRQoL) improvement in newly diagnosed multiple myeloma patients treated with bortezomib/melphalan/prednisone versus melphalan/prednisone: results from the VISTA trial. Proceedings of the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA; USA. Blood 2009; 114: Abstract 1881.
68. Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B et al. Patientreported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 1864.
69. Niesvizky R, Flinn I, Rifkin R, Gabrail N, Charu V, Clowney B et al. Patient-reported quality of life (QOL) in previously untreated, elderly multiple myeloma (MM) patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study. Proceedings of the 16th Congress of the European Hematology Association (EHA), London, United Kingdom. Haematologica 2011; 96: 123 (Abstract 0298).
70. Niesvizky R, Flinn IW, Rifkin RM, Gabrail NY, Veena Charu V, Clowney B et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Proceedings of the 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA. Blood 2010; 116: Abstract 619.
71. Niesvizky R, Reeves J, Flinn I, Gabrail N, Rifkin R, Charu V et al. Phase 3b UPFRONT study: interim results from a community-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients. Proceedings of the 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. Haematologica 2010; 95: 144 (Abstract 0358).
72. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-1060.
73. Dimopoulos M, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P et al. Melphalan, prednisone and lenalidomide followed by lenalidomide maintenance improves health-related quality of life (HRQoL), with newly diagnosed multiple myeloma (NDMM) patients Z65 years benefiting from delays in disease progression. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 3157.
74. Dimopoulos M, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P et al. Melphalan, prednisone and lenalidomide followed by lenalidomide maintenance displays treatment characteristics favourable to global quality of life in newly diagnosed multiple myeloma (NDMM) patientsZ65 years. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 3988.
75. Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P et al. Lenalidomide plus melphalan and prednisone followed by lenalidomide maintenance provides favourable efficacy and health-related quality-of-life in newly diagnosed multiple myeloma patients Z65 years. Proceedings of the 16th Congress of the European Hematology Association (EHA), London, United Kingdom. Haematologica 2011; 96: 365 (Abstract 0880).
76. Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 2013; 98: 784-788.
77. Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Chamorro CM et al. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 2012; 53: 1714-1721.
78. Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez Chamorro C et al. Safety, efficacy, and quality-of-life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma: the Spanish experience. Proceedings of the 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA. Blood 2010; 116: Abstract 3045.
79. Yong K, Alegre Amor A, Browne P, Cavenagh J, Dodds T, Greil R et al. A multicenter, single-arm, open-label safety and quality of life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma. Proceedings of the 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. Haematologica 2010; 95: 392 (Abstract 0944).
80. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in healthrelated quality of life. Med Care 1999; 37: 469-478.
81. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 861-873.
82. Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011; 20: 653-664.
83. Levy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F et al. Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. Leukemia 2001; 15: 1466-1470.
84. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231-239.
85. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
86. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
87. Gulbrandsen N, Wisloff F, Brinch L, Carlson K, Dahl IM, Gimsing P et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001; 18: 65-77.
88. Uyl-de Groot CA, Buijt I, Gloudemans IJ, Ossenkoppele GJ, Berg HP, Huijgens PC. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005; 74: 136-143.
89. Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996; 92: 604-613.
90. Wisloff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997; 97: 29-37.
91. Schunemann HJ, Guyatt GH. Commentary-goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res 2005; 40: 593-597.
92. Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007; 43: 1670-1678.
93. Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999; 104: 605-611.
94. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 2013, e-pub ahead of print 2 April 2013 doi:10.1007/ s11136-013-0379-8.
95. Wagner LI, Robinson Jr. D, Weiss M, Katz M, Greipp P, Fonseca R et al. Content development for the functional assessment of cancer therapy-multiple myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage 2012; 43: 1094-1104.
96. Weiss M, Jacobus S, Wagner LI, Cella D, Katz MS, Rajkumar V et al. Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) scale and validation in the Eastern Cooperative Oncology Group Trial E1A05. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA; USA. Blood 2011; 118: Abstract 4184.
97. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
98. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-561.
99. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13: 741-748.
100. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol 2011; 87: 330-337.